Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOT MBX SD-202
- Development stage
- Phase 1
- Lead developer
- Mybiotics Pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MOT MBX SD-202 (also known as MBX-SD-202) is an orally administered, lyophilized donor-derived whole microbiome therapeutic developed by MyBiotics Pharma. It is manufactured using the company's proprietary SuperDonor whole-microbiome culturing technology, which enables the standardized and scalable reproduction of complex live microbial populations from donor fecal samples. This technology serves as a safer, more consistent, and scalable alternative to traditional fecal microbiota transplantation (FMT). MOT MBX SD-202 is designed to restore microbial equilibrium and treat recurrent and severe cases of Clostridioides difficile infection (CDI) in patients who have already undergone antibiotic treatment. A Phase 1 clinical trial in healthy volunteers demonstrated that the capsule formulation is safe and well-tolerated across multiple doses.
Beyond the preview
Go deeper on MOT MBX SD-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOT MBX SD-202.